A Pediatric Case of Transformed Mycosis Fungoides in a BRCA2 Positive Patient

Andrea M Gross1,2, Joyce Turner1, Anna Y Kirkorian1

  • 1Children's National Medical Center, Washington, DC.

Insights

This study details a rare pediatric case of transformed mycosis fungoides in a child with a BRCA2 mutation. It highlights the uncommon nature of this aggressive malignancy and the potential link to germline mutations.

Area of Science:

  • Pediatric Oncology
  • Dermatology
  • Cancer Genetics

Background:

  • Cutaneous T-cell lymphomas (CTCLs) are exceptionally rare in children.
  • Mycosis fungoides is the most common CTCL in pediatric patients, but transformation to advanced stages is very uncommon.
  • Clinical management guidelines for pediatric CTCLs are lacking.

Observation:

  • Next-generation sequencing is increasingly used in pediatric oncology, potentially identifying germline mutations.
  • The clinical significance of discovered germline mutations in pediatric cancers is not always clear.
  • A unique case of transformed mycosis fungoides in a pediatric patient with a known BRCA2 mutation is presented.

Findings:

  • The case highlights a rare instance of aggressive CTCL progression in a child.
  • The presence of a BRCA2 mutation in this pediatric patient suggests a potential, though not fully elucidated, association with the disease.
  • This case underscores the complexity of diagnosing and managing rare pediatric malignancies.

Implications:

  • This case may inform future research into the genetic underpinnings of pediatric CTCLs.
  • Further investigation is needed to understand the role of germline mutations like BRCA2 in pediatric mycosis fungoides.
  • This report contributes to the limited literature on managing transformed mycosis fungoides in children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
276
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
203
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
262
Bacterial Transformation01:33

Bacterial Transformation

In 1928, bacteriologist Frederick Griffith worked on a vaccine for pneumonia, which is caused by Streptococcus pneumoniae bacteria. Griffith studied two pneumonia strains in mice: one pathogenic and one non-pathogenic. Only the pathogenic strain killed host mice.
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
59.5K